Belfast Health and Social Care Trust
caring supporting improving together

FOI/27564

27 July 2022

Biological Treatments for Breast Cancer

In the past 3 months, how many Breast Cancer patients (any stage) were treated with:

Abemaciclib monotherapy
- <5

Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole)
- this would be prescribed by the GP

Tamoxifen monotherapy
- this would be prescribed by the GP

Abemaciclib + Tamoxifen
- this would be prescribed by the GP

Abemaciclib + Tamoxifen + Goserelin
- this would be prescribed by the GP

Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) + Goserelin
- <5 (however the letrozole part is prescribed by the GP

Aromatase inhibitor + Goserelin
- this would be prescribed by the GP

Tamoxifen+ Goserelin
- this would be prescribed by the GP

How many patients have been treated for Triple-Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
- this is not for triple-negative only so unable to get figures

Atezolizumab +Nab-paclitaxel/Paclitaxel
- <5
- Pembrolizumab
- <5

Sacituzumab Govitecan
- <5

Parp Inhibitors (Olaparib/Talazoparib)
- <5

Eribulin as a single agent or in combination
- <5

Capecitabine as a single agent
- this is not for triple-negative only so unable to get figures

Platinum (e.g. carboplatin or cisplatin) as a single agent
- this is not for triple-negative only so unable to get figures

Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- this is not for triple-negative only so unable to get figures

Taxane and/or Anthracycline in combination
- this is not for triple-negative only so unable to get figures

Any other active systemic anti-cancer therapy
- EC-PC 9

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.